Gregory D. Phelps (1)
* Dr. Kobyzev and Mr. Phelps
are not standing for re-election to the Board at the Annual Meeting.
As of the date of the Annual Meeting, each of Dr. Kobyzev and Mr. Phelps will no longer be directors of the Company and will no longer serve on any committee of the Board.
Gregory D. Phelps has been a member of our Board since February 2008 and has served as Chairman of the Board since July 2009.
Mr. Phelps is an independent advisor to biotechnology and pharmaceutical companies.
He was a founder and Partner of Red Sky Partners LLC, an advisory firm providing corporate development, product strategy and leadership support to life sciences companies, from February 2009 to February 2014.
Prior to that, Mr. Phelps served as Chairman and Chief Executive Officer of RenaMed Biologics, Inc. from 2004 to 2007.
Prior to that, he served as Chief Executive Officer of Ardais Corporation from 2002 to 2003, as Vice Chairman and member of the executive committee of Dyax Corporation from 1998 to 2002, as Executive Vice President and Senior Vice President of Genzyme Corporation from 1991 to 1997.
Mr. Phelps has previously served as a member of the board of directors of the following companies: EPIX Pharmaceuticals Inc. from 2004 to 2009, Ostex International Inc. from 1995 to 2001, Atlantic Biopharmaceuticals (now Merrimack Pharmaceuticals Inc.) from 1998 to 2000, Neozyme II Corporation from 1992 to 1996, and Genzyme Transgenics Corporation (now rEVO Biologics Inc.) from 1993 to 1995.
Mr. Phelps received a B.S. in electrical engineering from Bradley University and an M.B.A. from Harvard Business School.
We believe Mr. Phelps is qualified to serve as a member of our Board because of his business and professional experience.
Bohlin, Canute, Haines, Kingsley and Phelps and Drs. Birner, Freund, Kobyzev and O'Leary, other than Timothy Noyes, our President and Chief Executive Officer, has no relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and is independent within the meaning of the director independence standards of the NASDAQ rules and the SEC.
Gregory D. Phelps is the Chairman of the Board.
The independent members of the Board periodically review the Board's leadership structure and have determined that Proteon
and our stockholders are well served with this structure.
Gregory D. Phelps
is not standing for re-election to the Board at the Annual Meeting.